Complement Regulatory Protein CD46 Manifests a Unique Role in Promoting the Migration of Bladder Cancer Cells

Sep 24, 2026

Uploaded by Grenda

Study evaluates membrane complement regulatory protein CD46 and its contribution to bladder cancer progression. CD46 is identified as overexpressed in bladder cancers and functions as a receptor for cancer therapeutic viruses while protecting host cells from complement injury. DNA microarray profiling in CD46-altered HT1376 cells highlights multiple target genes, and quantitative RT-PCR and Western blot validate CD46-mediated regulation of C3α, MGP, and keratin-related pathways. Functional migration assays show CD46 enhances bladder cancer migratory potential, supporting a CD46-driven role in metastasis-related motility.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages7

Reading Time18 min

AccessFree to download

Introduction

Materials and Methods

Cell lines and cell culture

Original Article [www.cmj.ac.kr](www.cmj.ac.kr) Complement Regulatory Protein CD46 Manifests a Unique Role in Promoting the Migration of Bladder Cancer Cells Thuy Thi Nguyen†, Hien Duong Thanh†, Manh-Hung Do, and Chaeyong Jung* Department of Anatomy, Chonnam National University Medical School, Gwangju, Korea CD46 is a membrane-bound complement regulatory protein (mCRP) possessing a regulatory role with the complement system. CD46 protects the host cells from damage by complement. Expression of CD46 is also highly maintained in many cancers, including bladder cancers, and thus functions as a receptor for many cancer therapeutic viruses. In this study we report a unique role ofCD46 as a progression factor of cancer cells in bladder cancers. Resulting data from a DNA microarray using CD46-altered HT1376 bladder cancers demonstrated a pool of target genes, including complement C3 􀁄 chain (C3􀁄), matrix Gla protein (MGP), AFAP-AS1, follicular dendritic cell secreted protein (FDCSP), MAM domain containing 2 (MAMDC2), gamma-aminobutyric acid A receptor pi (GABRP), transforming growth factor, beta-induced (TGFBI), a family of cytochrome P450 (CYP24A1), sialic acid binding Ig-like lectin 6 (SIGLEC6), metallothionein 1E (MT1E), and several members of cytokeratins. Subsequent studies using quantitative RT-PCR and Western blot analyses confirmed CD46-mediated regulation of C3􀁄, MGP, and keratin 13 (KRT13) . MGP and KRT13 are known tobe involved in cell migration and cancer cell metastasis. A cell migration assay demonstrated that CD46 enhanced migratory potential of bladder cancer cells. Taken all together, this report demonstrated that CD46 is generally overexpressed in bladder cancers and plays a unique role in the promotion of cancer cell migration. Further detailed studies are needed tobe performed to clarify the action mechanism of CD46 and its application to cancer therapeutics. KeyWords: CD46; mCRP; Urinary Bladder Neoplasms This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([http://creativecommons.org/licenses/by-nc/4.0](http://creativecommons.org/licenses/by-nc/4.0)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Article History: Received August 9, 2023 Revised September 1, 2023 Accepted September 4, 2023 Corresponding Author: Chaeyong Jung Department of Anatomy, Chonnam National University Medical School, 264 Seoyang-ro, Hwasun-eup, Hwasun 58128, Korea Tel: +82-61-379-2705 E-mail: [chjung@jnu.ac.kr](chjung@jnu.ac.kr) †These authors contributed equally to this work. INTRODUCTION There have been an estimated 82,290 diagnoses ofbladder cancer in the United States in 2023.1 Men are 4 times more likely than women to be diagnosed with the disease. Among men, bladder cancer is the fourth most common cancer. It is the eighth most common cause of cancer death among men with an estimated 16,710 deaths from this disease expected in the United States in 2023. In 2020, an estimated 212,536 people worldwide died from bladder cancer. Bladder cancers are mostly urothelial carcinoma, also called transitional cell carcinoma that originates from theurothelial cells of the bladder, the urethra, ureters and the outer track of the kidneys.2 Cancers can be treated with var- ious approaches including surgery, intravesicular therapy using BCG, chemotherapy, radiotherapy, targeted therapy, and immunotherapy.3 Despite of recent interest in various immunotherapy which utilizes the body’s immune system to recognize and attack cancer cells and offers amore targeted and potentially effective approach compared to traditional treatments, not all patients respond to immunotherapy, and ongoing research is aimed at understanding the factors that determine treatment response and resistance. CD46, also known as membrane cofactor protein (MCP), is a membrane-bound complem

FAQs

What is CD46 and why is it relevant to bladder cancer?

CD46 is a membrane-bound complement regulatory protein that protects host cells from complement damage. The article notes CD46 is highly maintained in cancers, including bladder cancer, and explores a direct role in cancer progression beyond immune protection.

How did the study identify genes regulated by CD46?

The study used DNA microarray analysis on CD46-altered HT1376 bladder cancer cells. It reported a set of target genes, including C3α chain and MGP, then confirmed key regulation using quantitative RT-PCR and Western blot.

What experimental evidence supports that CD46 promotes cancer cell migration?

A cell migration assay showed CD46 enhanced the migratory potential of bladder cancer cells. The authors conclude CD46 generally overexpresses in bladder cancers and promotes migration, contributing to metastasis-related behavior.

Sep 24, 2026

Uploaded by Grenda